Compare Herbalife Nutrition Ltd (HLF) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Incyte Corporation — how do they compare? Herbalife Nutrition Ltd trades at $12.23 (market cap $1.27B), while Incyte Corporation trades at $115.71 (market cap $23.11B). The key difference: Incyte Corporation is far larger — about 18.2× Herbalife Nutrition Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals.
| HLF | INCY | |
|---|---|---|
Market Cap | $1.27B | $23.11B |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $118.52 |
52-Week Low | $7.75 | $67.38 |
Enterprise Value | $3.00B | $19.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.25, up 2.17% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.64, beating expectations, and raised full-year guidance. Revenue remains stable around $5 billion annually, with a net income margin of 4.66%. Valuation ratios appear attractive with a P/E of 5.26 and P/S of 0.25. Debt-to-asset ratio improved to 71.67% in 2025, reflecting progress in deleveraging.
The outlook is mixed: strong analyst support (57.69% buy ratings) and operational improvements contrast with high debt levels and negative shareholder equity. Key risks include competitive pressures and reliance on international growth. Near-term catalyst is Q2 2026 earnings on August 5, 2026.
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
